-+ 0.00%
-+ 0.00%
-+ 0.00%
Taiyu Pharmaceutical submitted a clinical trial application for an antibody-drug conjugate biosimilar TSY-110 for HER2-positive breast cancer.
Share
Listen to the news
Taiyu Pharmaceutical submitted a clinical trial application for an antibody-drug conjugate biosimilar TSY-110 for HER2-positive breast cancer.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending